Back to results
US 8,008,266 B2Granted
Methods of treating cancer using immunostimulatory oligonucleotides
AssigneesUniversity of Iowa Foundation, The United States of America as represented by the Department of Health and Human Services, Coley Pharmaceutical Group, Inc.
InventorsArthur M. Krieg, Alfred D. Steinberg, Dennis Klinman
Life of this patent
Estimating the term…
Abstract
Nucleic acid sequences containing unmethylated CpG dinucleotides that modulate an immune response including stimulating a Th1 pattern of immune activation, cytokine production, NK lytic activity, and B cell proliferation are disclosed. The sequences are also useful as a synthetic adjuvant.
Claims30
A method for treating cancer, comprising:
- administering to a human subject an effective amount for treating cancer of a CpG immunostimulatory oligonucleotide having at least one unmethylated CpG dinucleotide, wherein at least one nucleotide of the stabilized CpG immunostimulatory oligonucleotide has a phosphate backbone modification and wherein the oligonucleotide is 8 to 100 nucleotides in length, wherein the phosphate backbone modification is a phosphorothioate modification, further comprising administering an antigen.
A method for treating non small cell lung carcinoma (NSCLC) in a human subject, comprising
- administering to a human subject having NSCLC an effective amount to treat NSCLC of an immunostimulatory oligonucleotide that includes at least one unmethylated CpG dinucleotide, wherein the immunostimulatory oligonucleotide includes a phosphate backbone modification and, wherein the oligonucleotide is 8 to 100 nucleotides in length, wherein the phosphate backbone modification is a phosphorothioate modification, further comprising administering an antigen.
Dependencies are inferred from the claim text.